(@zbigniew.m.szczepiorkowski)

Goal 4: Develop Workforce and Resources

DEVELOPMENT AND SUPPORT FOR APHERESIS MEDICINE INVESTIGATORS

The apheresis medicine encompasses treatment of numerous diseases many of which are directly related to blood, lung and heart. However, there are very limited opportunities for training young investigators in basic and translational research related to Apheresis Medicine. There is a need to promote Apheresis Medicine as a viable field of research for junior and established investigators. The influx of well-trained junior ...more »

Voting

108 net votes
127 up votes
19 down votes
Active
(@zbigniew.m.szczepiorkowski)

Goal 3: Advance Translational Research

TREATMENT OF SEPSIS-MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS) UTILIZING APHERESIS BASED STRATEGIES

Sepsis, a systemic inflammatory response to infection, is the most common cause of death in non-cardiac intensive care units. The incidence and severity of sepsis have increased over the last two decades. With advances in supportive care, sepsis carries a mortality that averages 17%, however, this figure increases to 50 - 80% in Multiple Organ Dysfunction Syndrome (MODS), defined as failure of 3 or more organ systems. ...more »

Voting

97 net votes
115 up votes
18 down votes
Active
(@bconklin)

Goal 3: Advance Translational Research

Use isogenic iPS cells to advance Precision Medicine

The goals of Precision Medicine can be achieved if we determine the biological basis of disease-associated variants for NHLBI diseases. Advances in genetic research have yielded hundreds of disease-associated DNA polymorphisms, yet we lack robust methods to experimentally test their functional relevance in human cells. Determining the molecular and cellular basis of human phenotypic variation is one of the great challenges ...more »

Voting

-19 net votes
8 up votes
27 down votes
Active
(@nhlbiforumadministrator)

Goal 4: Develop Workforce and Resources

Preserving and promoting expertise in integrative physiology

From my perspective, one of the key “critical challenges” facing the NHLBI in particular, and medical science in general, is to avoid being blinded by the promises of the reductionists in the “personalized, precision medicine” of the future. In order to understand the advances being made at the molecular level, we need to preserve and promote expertise in truly integrative physiology, what I like to call “PHYSIOMICS”. ...more »

Voting

6 net votes
16 up votes
10 down votes
Active
(@nhlbiforumadministrator)

Goal 3: Advance Translational Research

Improving heart, lung, blood, sleep Health Outcomes for Minority and Underserved Men

What are the best strategies to improve implementation of evidence-based practices (EBP) to enhance effective health risk communication strategies among racial and ethnic minority males and underserved men? Examples of several issues that need to be addressed are: • Need for better definition of the role of families/communities in EBP (as co-therapists). • Requires less system fragmentation • Need for improved measurement, ...more »

Voting

14 net votes
32 up votes
18 down votes
Active
(@heartjpc)

Goal 1: Promote Human Health

New technologies for Personalized health monitoring: too much or not enough

The development of personalized medicine and the increasing amount of information extracted from individual and patients throughout their life is expected to growth significantly. Multiple types of physiological sensors are currently embedded in everyday-life objects and yet their clinical value and their potential to improve health care is not well defined. It seems fundamental that the NIH develops a core research group/ ...more »

Voting

5 net votes
13 up votes
8 down votes
Active
(@chuck.sanders)

Goal 2: Reduce Human Disease

Bringing Personalized Biochemistry and Biophysics to Bear on Problems of Personalized Heart, Lung and Blood Medicine

Precision medicine will provide unprecedented opportunities to tailor health care based on knowledge of personal patterns of genetic variations. These variations usually impact protein or RNA sequences, resulting in altered properties. These alterations can result in increased susceptibility to a particular disease or intolerance to common therapeutics. To take full advantage of knowing a patient’s set of gene variations, ...more »

Voting

-2 net votes
9 up votes
11 down votes
Active
(@yanyunw)

Goal 2: Reduce Human Disease

Study on key product factors for optimal Bone Marrow Transplantation (BMT) graft function

Hematopoietic progenitor cells (HPC) collected by Apheresis is the most common source used for BMT. How the cells are collected and what kinds of cells are collected can affect BMT graft function. Limited studies have been done to study the key product factors in relationship to optimal graft function. Questions remain such as the optimal lymphocytes contents for reduced infection post BMT, optimal megakaryocyte precursor ...more »

Voting

70 net votes
93 up votes
23 down votes
Active
(@jnoel0)

Goal 2: Reduce Human Disease

DEVELOPMENT OF A PERSONALIZED APPROACH TO SLEEP AND CIRCADIAN DISORDERS

There is developing evidence of major individual differences in pathways to different common sleep disorders such as obstructive sleep apnea. Moreover, there is evidence of different clinical presentations of disease and different outcomes. For example, some subjects with obstructive sleep apnea who get excessive sleepiness while others do not. The latter are still at risk for other consequences of the disorder such ...more »

Voting

167 net votes
220 up votes
53 down votes
Active
(@js2745)

Goal 2: Reduce Human Disease

The role of Extracorporeal Photopheresis (ECP) in the prophylaxis and treatment of acute & chronic Graft Versus Host Disease

In Acute Graft Versus Host Disease (aGVHD), we would like to examine whether early and intensified delivery of ECP as part of standard prophylaxis will decrease overall corticosteroid exposure while preserving expected relapse rates in patients undergoing unrelated donor hematopoietic stem cell transplantation (HSCT). Chronic GVHD (cGVHD) is common after HSCT (30-50% recipients) and is a major contributor to late transplant-related ...more »

Voting

103 net votes
126 up votes
23 down votes
Active